GSE161015 Transcriptome analysis the early and advanced stage of ovarian cancer

Contributor : Lixin ChenSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWe aim to explore the common gene between proteomics and transcriptomics and pathway mechanism related to layer classification. Our results will provide several potential biomarkers in early diagnosis of ovarian cancer.Transcriptomics methods were performed to compare the differences between early ovarian cancer specimens (n = 3, stage Ⅰ / Ⅱ) and advanced ovarian cancer specimens (n = 6, stage Ⅲ / Ⅳ), and the similarities and differences of the data obtained were analyzed.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Related Links:

Condition:   Ovarian Cancer Intervention:   Biological: fhB7H3.CAR-Ts Sponsors:   The Affiliated Hospital of Xuzhou Medical University;   Xuzhou Medical University;   IIT MediTech (Jiangsu) Co. Ltd Recruiting
Source: - Category: Research Source Type: clinical trials
Reproduction. 2022 Jan 1:REP-21-0361.R1. doi: 10.1530/REP-21-0361. Online ahead of print.ABSTRACTPolycomb repressive complex 2 (PRC2) catalyses the repressive epigenetic modification, histone 3 lysine 27 tri-methylation (H3K27me3) and functions as a key epigenetic regulator during embryonic development. PRC2 is known to regulate the development of a range of tissues by transcriptional silencing of genes that control cell differentiation, but its roles in female germline and ovarian development remain unknown. Using a mouse model with hypomorphic EED function that reduced H3K27me3 in somatic and germ cells, we found that PR...
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research
In conclusion, TOP2 dysfunction causes MI arrest by activating Aurora B, SAC and MPF and it prevents PB1 abscission by promoting chromatin bridges.PMID:35084021 | DOI:10.1093/biolre/ioac011
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research
Contributors : Iris Lodewijk ; Alejandra Bernardini ; Cristian Su árez-Cabrera ; Elsa Bernal ; Rodrigo Sánchez ; Juan L Garcia ; Katerin Rojas ; Lucía Morales ; Sarah Wang ; Xinwei Han ; Marta Dueñas ; Jesús M Paramio ; Luis MansoSeries Type : OtherOrganism : Homo sapiensWe explore the potential of immune-associated expression profiles in a series of Epithelial Ovarian Cancer (EOC) patients undergoing neoadjuvant chemotherapy (NACT), comparing primary lesions before patients underwent carboplatin/paclitaxel-based NACT (so-called ´biopsy samples´) and interval debulking surgery...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Other Homo sapiens Source Type: research
d Mesía Anna Martínez-Cardús Ester Ballana Mireia Margelí SAMHD1 is a deoxynucleotide triphosphate (dNTP) triphosphohydrolase with important roles in the control of cell proliferation and apoptosis, either through the regulation of intracellular dNTPs levels or the modulation of the DNA damage response. However, SAMHD1′s role in cancer evolution is still unknown. We performed the first in-depth study of SAMHD1′s role in advanced solid tumors, by analyzing samples of 128 patients treated with chemotherapy agents based on platinum derivatives and/or antimetabolites, d...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Smrkolj Špela Smrkolj In the last ten years, clinical oncology has been revolutionized by the introduction of oncological immunotherapy, mainly in the form of immune checkpoint inhibitors (ICIs) that transformed the standard of care of several advanced solid malignancies. Using ICIs for advanced gynecological cancers has yielded good results, especially for endometrial cancer. In ovarian or cervical cancer, combining ICIs with other established agents has shown some promise. Concurrently with the clinical development of ICIs, biomarkers that predict responses to such therapy have been discovered and used in cl...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
ConclusionScanning the ovarian cancer secretome datasets provides the opportunity to identify if tumor-specific biomarkers could be tested as secretory biomarkers. Detecting their levels in the body fluid would be more advantageous than evaluating the expression in the tissue, since it could be monitored multiple times over the course of the disease to have a better judgment of the prognosis and response to therapy.
Source: Archives of Gynecology and Obstetrics - Category: OBGYN Source Type: research
IJERPH, Vol. 19, Pages 1404: Predicting Ovarian-Cancer Burden in Catalonia by 2030: An Age–Period–Cohort Modelling International Journal of Environmental Research and Public Health doi: 10.3390/ijerph19031404 Authors: Paula Peremiquel-Trillas Jon Frias-Gomez Laia Alemany Alberto Ameijide Mireia Vilardell Rafael Marcos-Gragera Sònia Paytubi Jordi Ponce José Manuel Martínez Marta Pineda Joan Brunet Xavier Matías-Guiu Marià Carulla Jaume Galceran Ángel Izquierdo Josep M. Borràs Laura Costas Ramon Clèries Ovarian cance...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
Mortality rates from most major cancers are predicted to continue falling in Europe and the UK in 2022, with a particularly striking reduction in deaths from ovarian cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Mesothelin (MSLN) is an excellent target for antibody-based therapies of cancer because of its high expression in many malignancies but lack of expression on essential normal tissues. Unfortunately, a large fragment of MSLN is shed from cancer cells, causing the currently available anti-MSLN antibodies (and immunoconjugates thereof) which bind to the shed portion of MSLN to quickly lose their therapeutic effectiveness over time. Indeed, the shed portion of MSLN can act as a decoy for these antibodies, further limiting them from reaching and destroying tumor cells.Scientists at the National Cancer Institute (NCI) previously...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Tags: Therapeutics Licensing Desired NCI Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Ovarian Cancer | Ovaries